Contrasting Moolec Science (MLEC) and Its Rivals

Moolec Science (NASDAQ:MLEC) is one of 673 public companies in the “Holding & other investment offices” industry, but how does it contrast to its peers? We will compare Moolec Science to related businesses based on the strength of its profitability, institutional ownership, dividends, valuation, analyst recommendations, risk and earnings.

Risk & Volatility

Moolec Science has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 0.03, meaning that their average stock price is 97% less volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 54.3% of shares of all “Holding & other investment offices” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by company insiders. Comparatively, 26.7% of shares of all “Holding & other investment offices” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Moolec Science and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.62 million	-$7.31 million	-4.40
Moolec Science Competitors	$1.04 billion	$84.35 million	62.54

Moolec Science’s peers have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for Moolec Science and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	128	730	961	19	2.47

Moolec Science currently has a consensus target price of $6.00, suggesting a potential upside of 581.82%. As a group, “Holding & other investment offices” companies have a potential upside of 56.60%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities analysts plainly believe Moolec Science is more favorable than its peers.

Profitability

This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-97.95%	-27.91%
Moolec Science Competitors	-17.66%	-43.09%	-0.30%

Summary

Moolec Science peers beat Moolec Science on 10 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.